Belgium · Biotechnology startup
Belgium · eTheRNA immunotherapies
eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.
Funding reportedLast round: Series B
What company datasets say eTheRNA immunotherapies raised
Funding, as reported
Reported in all111.9Min the source's currency
Rounds5
Last roundSeries B
Last round dateAug 2022
Investors listed14
Founders and team
From eTheRNA immunotherapies's own website: 5 on the team.
- Bernard SagaertChief Executive Officer
- Philip Van der AuweraVP HR & Operations
- Stefaan De KokerVP Technology & Innovation
- Florence LambolezDirector Pharmacology
- Lien VangansewinkelFinance Director
On a portfolio page
Investors who name them
Each firm lists eTheRNA immunotherapies on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Belgium
Startups like it
Is this your company?
Add your raise, your deck and your story, and put eTheRNA immunotherapies in front of investors. Or tell us what we have wrong.